Semi-personalised medicine: a new model for cost-effective precision
March 31st 2025
While fully personalised medicine has long been heralded as the gold standard in healthcare, its real-world applications are often limited by cost and complexity.
That’s why the emergence of “semi-personalised” medicine is gaining traction as a more feasible and scalable alternative.
Rather than tailoring treatments to individual genomes, this approach looks at shared biomarkers across patient populations to develop targeted yet broadly applicable therapies. For instance, a cancer study cited during the round table found that 80% of colorectal and oesophageal cancer patients had specific, identifiable epitopes. Such findings suggest that tailored treatments based on population subgroups rather than individuals can still yield excellent clinical outcomes.
This model offers a pragmatic path forward. It balances the precision of personalised medicine with the cost-effectiveness and scalability needed for widespread adoption. “That is quite good enough,” said one panel participant. “I think semi-personalised medicine may take the mainstream.”
“I think semi-personalised medicine may take the mainstream.”
As computing power grows and data analytics improve, the potential for semi-personalised approaches will only increase, especially in oncology and immunotherapy. For an industry constantly balancing innovation with affordability, this may be one of the most important developments of the next decade.
Are you seeking a trusted partner to support your executive search in Life Sciences?
We bring decades of executive search experience and a proven track record of success across our dedicated sectors. Our investor clients rely on us time and again to build exceptional leadership teams that drive growth and deliver results.
